These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 38564694)

  • 1. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
    Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
    Microbiol Spectr; 2024 Aug; 12(8):e0078724. PubMed ID: 38916354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis.
    Ledger EL; Smith DJ; Teh JJ; Wood ME; Whibley PE; Morrison M; Goldberg JB; Reid DW; Wells TJ
    J Infect Dis; 2024 Sep; 230(3):e536-e547. PubMed ID: 38442240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.
    Loske J; Völler M; Lukassen S; Stahl M; Thürmann L; Seegebarth A; Röhmel J; Wisniewski S; Messingschlager M; Lorenz S; Klages S; Eils R; Lehmann I; Mall MA; Graeber SY; Trump S
    Am J Respir Crit Care Med; 2024 Jun; 209(11):1338-1350. PubMed ID: 38259174
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
    Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
    J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.
    Zemanick ET; Emerman I; McCreary M; Mayer-Hamblett N; Warden MN; Odem-Davis K; VanDevanter DR; Ren CL; Young J; Konstan MW;
    J Cyst Fibros; 2024 Jul; 23(4):676-684. PubMed ID: 38360461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor.
    Gavey R; Nolan J; Moore V; Reid D; Brown J
    J Cyst Fibros; 2024 Sep; 23(5):1024-1026. PubMed ID: 38777631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis.
    Dittrich AM; Sieber S; Naehrlich L; Burkhart M; Hafkemeyer S; Tümmler B;
    Int J Infect Dis; 2024 Feb; 139():124-131. PubMed ID: 38036261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.
    Marsh R; Santos CD; Yule A; Dellschaft NS; Hoad CL; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
    J Cyst Fibros; 2024 Sep; 23(5):967-976. PubMed ID: 38749891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
    Yule A; Ng C; Recto A; Lockwood F; Dellschaft NS; Hoad CL; Zagoya C; Mainz JG; Major G; Barr HL; Gowland PA; Stewart I; Marciani L; Spiller RC; Smyth AR
    J Cyst Fibros; 2024 Sep; 23(5):984-990. PubMed ID: 39242338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
    Stewart KL; Szczesniak R; Liou TG
    Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.
    Blardone C; Gambazza S; Mariani A; Galgani R; Brivio A; Nobili RM; Rizza C; Tutino AL; Gramegna A; Daccò V; Contarini M; Blasi F; Laquintana D
    Ther Adv Respir Dis; 2024; 18():17534666241235054. PubMed ID: 38554035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 17. Is Obesity a Problem in New Cystic Fibrosis Treatments?
    Solís-García M; García-Clemente MM; Madrid-Carbajal CJ; Peláez A; Gómez Punter RM; Eiros Bachiller JM; Girón Moreno RM
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators.
    Lanfranchi C; Rizza C; Russo MC; Borzani I; Angileri SA; Nazzari E; Alicandro G; Blasi F; Daccò V
    Int J Infect Dis; 2024 Oct; 147():107190. PubMed ID: 39053617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting.
    Daccò V; Rosazza C; Mariani A; Rizza C; Ingianni N; Nazzari E; Terlizzi V; Blasi FA; Alicandro G
    Pediatr Pulmonol; 2024 Nov; 59(11):2792-2799. PubMed ID: 38869349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
    Chun SW; Somers ME; Burgener EB
    Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.